At Upstream Bio we strive to reach the source of inflammation and conquer it. Their lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases. Upstream Bio is leveraging diverse roots and the team's substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/02/22 | $200,000,000 | Series A |
Access Biotechnology Altshuler Shaham Provident Funds Decheng Capital HBM Healthcare Investments Maruho Co.  Omega Funds OrbiMed Advisors Samsara BioCapital TCG | undisclosed |
